- Home
- OPFI vs NPCE Comparison
OPFI vs NPCE Comparison
Compare OPFI & NPCE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OPFI
- NPCE
- Stock Information
- Founded
- OPFI 2009
- NPCE 1997
- Country
- OPFI United States
- NPCE United States
- Employees
- OPFI N/A
- NPCE N/A
- Industry
- OPFI Finance: Consumer Services
- NPCE Medical Specialities
- Sector
- OPFI Finance
- NPCE Health Care
- Exchange
- OPFI Nasdaq
- NPCE Nasdaq
- Market Cap
- OPFI 300.3M
- NPCE 292.9M
- IPO Year
- OPFI N/A
- NPCE 2021
- Fundamental
- Price
- OPFI $10.17
- NPCE $9.15
- Analyst Decision
- OPFI Buy
- NPCE Strong Buy
- Analyst Count
- OPFI 2
- NPCE 6
- Target Price
- OPFI $11.75
- NPCE $16.67
- AVG Volume (30 Days)
- OPFI 1.3M
- NPCE 205.3K
- Earning Date
- OPFI 08-06-2025
- NPCE 08-12-2025
- Dividend Yield
- OPFI 9.79%
- NPCE N/A
- EPS Growth
- OPFI N/A
- NPCE N/A
- EPS
- OPFI N/A
- NPCE N/A
- Revenue
- OPFI $320,831,000.00
- NPCE $88,570,000.00
- Revenue This Year
- OPFI $116.69
- NPCE $22.13
- Revenue Next Year
- OPFI $9.90
- NPCE $6.07
- P/E Ratio
- OPFI N/A
- NPCE N/A
- Revenue Growth
- OPFI 31.26
- NPCE 23.32
- 52 Week Low
- OPFI $3.93
- NPCE $5.45
- 52 Week High
- OPFI $17.73
- NPCE $18.98
- Technical
- Relative Strength Index (RSI)
- OPFI 46.36
- NPCE 51.74
- Support Level
- OPFI $10.11
- NPCE $8.61
- Resistance Level
- OPFI $10.76
- NPCE $8.99
- Average True Range (ATR)
- OPFI 0.47
- NPCE 0.53
- MACD
- OPFI 0.08
- NPCE 0.11
- Stochastic Oscillator
- OPFI 51.49
- NPCE 75.00
About OPFI OppFi Inc.
OppFi Inc is a tech-enabled, mission-driven specialty finance platform that broadens the reach of community banks to extend credit access to everyday Americans. It recognizes revenue through finance charges on installment and SalaryTap contracts based on the interest method.
About NPCE Neuropace Inc.
NeuroPace Inc is a commercial-stage medical device company focused on transforming the lives of people suffering from epilepsy by reducing or eliminating the occurrence of debilitating seizures. It derives substantially all of its revenue from the sales of RNS Systems to hospital facilities (typically Level 4 CECs) that implant RNS Systems.